Global HIV Infection Pipeline Analysis

The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have been successful in improving the quality of life for HIV patients and prevented the virus from developing into AIDS. The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.6 in 2012, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-HIV-Infection-Pipeline-Analysis

“Global HIV Infection Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of HIV Infection. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process.

Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

HIV Infection Drug Development by Clinical Phase:

• Research: 31

• Preclinical: 140

• Phase-I: 53

• Phase-I/II: 18

• Phase-II: 39

• Phase-III: 7

• Preregistration: 2

• Registered: 2

• Marketed: 34

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.